Triple-Negative Breast Cancer (TNBC) Recruiting Phase 2 Trials for Docetaxel (DB01248)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03639948Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast CancerTreatment
NCT03154749TC (Docetaxel/Carboplatin) Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast CancerTreatment